



## Clinical trial results:

### FLOW – Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects with Type 2 Diabetes and Chronic Kidney Disease

#### Summary

EudraCT number	2018-002878-50
Trial protocol	GB HU NL SK BG DE ES FR PL BE GR IT
Global end of trial date	09 January 2024

#### Results information

Result version number	v1 (current)
This version publication date	24 January 2025
First version publication date	24 January 2025

#### Trial information

##### Trial identification

Sponsor protocol code	NN9535-4321
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03819153
WHO universal trial number (UTN)	U1111-1217-6259
Other trial identifiers	Japanese registration number: JapicCTI 194843

Notes:

##### Sponsors

Sponsor organisation name	Novo Nordisk A/S
Sponsor organisation address	Novo Allé, Bagsvaerd, Denmark, 2880
Public contact	Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com
Scientific contact	Clinical Reporting Office (2834), Novo Nordisk A/S, clinicaltrials@novonordisk.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 February 2024
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	09 January 2024
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Primary objective: To demonstrate that semaglutide delays the progression of renal impairment and lowers the risk of renal and cardiovascular mortality compared to placebo, both added to standard-of-care, in subjects with type 2 diabetes and chronic kidney disease

Protection of trial subjects:

This trial was conducted in accordance with the principles of the Declaration of Helsinki, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice, including the archiving of essential documents, and United States Food and Drug Administration (FDA) 21 Code of Federal Regulation (CFR) 312.50 and 312.56.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	17 June 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 159
Country: Number of subjects enrolled	United States: 706
Country: Number of subjects enrolled	Belgium: 51
Country: Number of subjects enrolled	Bulgaria: 75
Country: Number of subjects enrolled	France: 79
Country: Number of subjects enrolled	Germany: 73
Country: Number of subjects enrolled	Greece: 101
Country: Number of subjects enrolled	Hungary: 130
Country: Number of subjects enrolled	Italy: 94
Country: Number of subjects enrolled	Netherlands: 48
Country: Number of subjects enrolled	Poland: 78
Country: Number of subjects enrolled	Slovakia: 100
Country: Number of subjects enrolled	Spain: 72
Country: Number of subjects enrolled	United Kingdom: 62
Country: Number of subjects enrolled	Australia: 59
Country: Number of subjects enrolled	China: 30
Country: Number of subjects enrolled	India: 231
Country: Number of subjects enrolled	Israel: 61
Country: Number of subjects enrolled	Japan: 256

Country: Number of subjects enrolled	Malaysia: 82
Country: Number of subjects enrolled	Thailand: 109
Country: Number of subjects enrolled	Türkiye: 84
Country: Number of subjects enrolled	Argentina: 128
Country: Number of subjects enrolled	Brazil: 124
Country: Number of subjects enrolled	Mexico: 82
Country: Number of subjects enrolled	Russian Federation: 270
Country: Number of subjects enrolled	South Africa: 101
Country: Number of subjects enrolled	Ukraine: 88
Worldwide total number of subjects	3533
EEA total number of subjects	901

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1285
From 65 to 84 years	2218
85 years and over	30

## Subject disposition

### Recruitment

Recruitment details:

Subjects were randomised in 28 countries (383sites): Argentina-7; Australia-7;Belgium-8;Brazil-7; Bulgaria-7; Canada-25;China-4;France-11;Germany-9;Greece-13;Hungary-10;India-16;Israel-4;Italy-8;Japan-26;Malaysia-6;Mexico-6;Netherlands-9;Poland-7;Russia-21;Slovakia-10;South Africa-8;Spain-7;Thailand-6; Turkey-12; Ukraine-7;United Kingdom-11;US-111.

### Pre-assignment

Screening details:

A total of 5581 subjects were screened, of which 2042 were screening failures due to eligibility criteria not met. A total of 3539 eligible subjects were randomised (1:1) to treatment with semaglutide 1 milligram (mg) (1770) or placebo (1769). The study included a treatment period (up to 60 months or more) and a follow-up period (5 weeks).

### Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Carer, Data analyst, Assessor, Subject

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Semaglutide

Arm description:

Subjects received a dose of semaglutide subcutaneously once weekly with dose escalation in every 4 weeks in doses 0.25 mg (weeks 0-3), 0.50 mg (weeks 4-7) until the maintenance dose of 1 mg was reached at week 8 and continued 1 mg dose along with standard of care until end of the study (week 238). Subjects were followed up for 5 weeks.

Arm type	Experimental
Investigational medicinal product name	Semaglutide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide was administered once weekly subcutaneously.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Subjects received semaglutide matching placebo subcutaneously once weekly along with standard of care until end of the study (week 238). Subjects were followed up for 5 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Semaglutide matched placebo was administered once weekly subcutaneously.

<b>Number of subjects in period 1</b>	Semaglutide	Placebo
Started	1767	1766
Full Analysis Set (FAS)	1767	1766
Completed	1724	1708
Not completed	43	58
Consent withdrawn by subject	20	28
Lost to follow-up	23	30

## Baseline characteristics

### Reporting groups

Reporting group title	Semaglutide
-----------------------	-------------

Reporting group description:

Subjects received a dose of semaglutide subcutaneously once weekly with dose escalation in every 4 weeks in doses 0.25 mg (weeks 0-3), 0.50 mg (weeks 4-7) until the maintenance dose of 1 mg was reached at week 8 and continued 1 mg dose along with standard of care until end of the study (week 238). Subjects were followed up for 5 weeks.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received semaglutide matching placebo subcutaneously once weekly along with standard of care until end of the study (week 238). Subjects were followed up for 5 weeks.

Reporting group values	Semaglutide	Placebo	Total
Number of subjects	1767	1766	3533
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	633	652	1285
From 65-84 years	1123	1095	2218
85 years and over	11	19	30
Age Continuous Units: years			
arithmetic mean	66.6	66.7	
standard deviation	± 9.0	± 9.0	-
Gender Categorical Units: Subjects			
Female	519	550	1069
Male	1248	1216	2464

## End points

### End points reporting groups

Reporting group title	Semaglutide
Reporting group description: Subjects received a dose of semaglutide subcutaneously once weekly with dose escalation in every 4 weeks in doses 0.25 mg (weeks 0-3), 0.50 mg (weeks 4-7) until the maintenance dose of 1 mg was reached at week 8 and continued 1 mg dose along with standard of care until end of the study (week 238). Subjects were followed up for 5 weeks.	
Reporting group title	Placebo
Reporting group description: Subjects received semaglutide matching placebo subcutaneously once weekly along with standard of care until end of the study (week 238). Subjects were followed up for 5 weeks.	

**Primary: Time to first occurrence of a composite endpoint consisting of: onset of persistent  $\geq 50\%$  reduction in eGFR(CKD-EPI); onset of persistent eGFR(CKD-EPI)  $< 15\text{mL/min/1.73m}^2$ ; initiation of chronic renal replacement therapy; renal death; CV death**

End point title	Time to first occurrence of a composite endpoint consisting of: onset of persistent $\geq 50\%$ reduction in eGFR(CKD-EPI); onset of persistent eGFR(CKD-EPI) $< 15\text{mL/min/1.73m}^2$ ; initiation of chronic renal replacement therapy; renal death; CV death
End point description: Number of subjects from time of randomisation to first occurrence of an onset of persistent greater than or equal to ( $\geq$ ) 50 percent (%) reduction in estimated glomerular filtration rate (eGFR) (chronic kidney disease - epidemiology collaboration [CKD-EPI]) compared to baseline; onset of persistent eGFR (CKD-EPI) $< 15$ millilitre per minute per $1.73$ metre square ( $\text{mL/min/1.73 m}^2$ ); initiation of chronic renal replacement therapy (dialysis or kidney transplantation); renal death; and cardiovascular (CV) death combined that were reported in this endpoint. FAS included all unique randomised subjects who were grouped according to the treatment assigned at randomisation.	
End point type	Primary
End point timeframe: From randomisation (week 0) to end-of-trial (up to 61 months or more)	

End point values	Semaglutide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1767	1766		
Units: Subjects				
Total number of first composite renal event	331	410		

### Statistical analyses

Statistical analysis title	Semaglutide versus Placebo
Statistical analysis description: Time from randomisation to first composite renal event was analysed using a Cox proportional hazards model with treatment as categorical fixed factor and stratified by use of sodium glucose cotransporter-2 (SGLT-2) inhibitor (yes/no) at baseline. Based on the available number of events for analysis, the	

nominal significance level was updated to 0.01612 using the Lan-DeMets alpha spending function. eGFR was calculated using the CKD-EPI formula.

Comparison groups	Semaglutide v Placebo
Number of subjects included in analysis	3533
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0001
Method	Regression, Cox
Parameter estimate	Cox proportional hazard
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	0.88

### Secondary: Number of subjects from time of randomisation to time to first occurrence of a major adverse cardiovascular event (MACE): acute myocardial infarction (non fatal); non-fatal stroke; and CV death

End point title	Number of subjects from time of randomisation to time to first occurrence of a major adverse cardiovascular event (MACE): acute myocardial infarction (non fatal); non-fatal stroke; and CV death
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

#### End point description:

Number of subjects who reported first occurrence of non-fatal acute myocardial infarction, non-fatal stroke, and CV death combined data were presented from Week 0 up to Week 234 during on-treatment period. MACE consisted of non-fatal acute myocardial infarction, cardiovascular death and non-fatal stroke. First on-treatment period is defined as period from date of first dose until first time where no dose had been administered within 5 weeks (35 days) or end of the in-trial period, whichever came first. FAS included all unique randomised subjects who were grouped according to the treatment assigned at randomisation.

End point type	Secondary
----------------	-----------

#### End point timeframe:

From randomisation (week 0) to end-of-trial (up to 61 months or more)

End point values	Semaglutide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1767	1766		
Units: Subjects	212	254		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Time to occurrence of all-cause death

End point title	Time to occurrence of all-cause death
-----------------	---------------------------------------



**End point description:**

Number of subjects who reported occurrence of deaths from Week 0 up to Week 234 during in-trial period were presented. All cause death consisted of renal death, cardiovascular death, non-cardiovascular and non-renal death, and undetermined cause of death. In-trial observation period was defined as the period from date of randomisation to the first of (both inclusive): date of follow-up visit, date when subject withdrew consent, date of last contact with subject (for subject lost to follow-up), and date of death. FAS included all unique randomised subjects who were grouped according to the treatment assigned at randomisation.

End point type	Secondary
----------------	-----------

**End point timeframe:**

From randomisation (week 0) to end-of-trial (up to 61 months or more)

End point values	Semaglutide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1767	1766		
Units: Subjects				
All-cause death	227	279		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Annual rate of change in eGFR (CKD-EPI) (Total eGFR Slope)**

End point title	Annual rate of change in eGFR (CKD-EPI) (Total eGFR Slope)
-----------------	------------------------------------------------------------

**End point description:**

Annual rate of change in Total eGFR slope CKD-EPI were reported from baseline at Week 234 in-trial period. eGFR was calculated using the CKD-EPI formula. In-trial observation period was de-fined as the period from date of randomisation to the first of (both inclusive): date of follow-up visit, date when subject withdrew consent, date of last contact with subject (for subject lost to follow-up), and date of death. FAS included all unique randomised subjects who were grouped according to the treatment assigned at randomisation.

End point type	Secondary
----------------	-----------

**End point timeframe:**

From randomisation (week 0) to end-of-trial (up to 61 months or more)

End point values	Semaglutide	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1767	1766		
Units: mL/min/1.73 m <sup>2</sup> /year				
arithmetic mean (standard deviation)	-2.19 (± 0.1)	-3.36 (± 0.1)		

**Statistical analyses**



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Week 0 up to Week 238

Adverse event reporting additional description:

The safety evaluation was based on the FAS using the in-trial observation period which was defined as the period from date of randomisation to the first of (both inclusive): date of follow-up visit, date when subject withdrew consent, date of last contact with subject (for subject lost to follow-up), and date of death.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26
--------------------	----

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received semaglutide matching placebo subcutaneously once weekly along with standard of care until end of the study (week 238). Subjects were followed up for 5 weeks after end of treatment.

Reporting group title	Semaglutide
-----------------------	-------------

Reporting group description:

Subjects received a dose of semaglutide subcutaneously once weekly with dose escalation in every 4 weeks in doses 0.25 mg (weeks 0-3), 0.50 mg (weeks 4-7) until the maintenance dose of 1 mg was reached at week 8 and continued 1 mg dose along with standard of care until end of the study (week 238). Subjects were followed up for 5 weeks after end of treatment.

Serious adverse events	Placebo	Semaglutide	
Total subjects affected by serious adverse events			
subjects affected / exposed	950 / 1766 (53.79%)	877 / 1767 (49.63%)	
number of deaths (all causes)	279	227	
number of deaths resulting from adverse events	8	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	2 / 1766 (0.11%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Adenocarcinoma of colon			
subjects affected / exposed	7 / 1766 (0.40%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	1 / 7	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma pancreas			

subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 1	
Adenoma benign			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myeloid leukaemia			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Adrenal neoplasm			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal cancer			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiolipoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell small lymphocytic lymphoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign duodenal neoplasm			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of eyelid			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
B-cell lymphoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign neoplasm of thyroid gland			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct cancer			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			
subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder squamous cell carcinoma stage unspecified			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder transitional cell carcinoma			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cancer pain			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carcinoid tumour pulmonary			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangiocarcinoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chromophobe renal cell carcinoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic leukaemia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic lymphocytic leukaemia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clear cell renal cell carcinoma			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Colon cancer			
subjects affected / exposed	3 / 1766 (0.17%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer metastatic			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Colon cancer stage IV			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon neoplasm			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal adenoma			
subjects affected / exposed	1 / 1766 (0.06%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colorectal cancer			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ductal adenocarcinoma of pancreas			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenocarcinoma			

subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial cancer			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extranodal marginal zone B-cell lymphoma (MALT type)			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder neoplasm			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastric cancer			
subjects affected / exposed	0 / 1766 (0.00%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 0	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric cancer stage III			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal stromal tumour			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal tract adenoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glioblastoma			



subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic cancer			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hepatocellular carcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 3	
Invasive breast carcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Invasive lobular breast carcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Keratinising squamous cell carcinoma of nasopharynx			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intraductal papillary mucinous neoplasm			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal cancer stage 0			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laryngeal squamous cell carcinoma			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Light chain disease			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	6 / 1766 (0.34%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	1 / 6	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Lung adenocarcinoma stage 0			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma stage IV			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung cancer metastatic			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Lymphoplasmacytoid lymphoma/immunocytoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Lung neoplasm			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Malignant melanoma</b>			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Meningioma</b>			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Malignant neoplasm of unknown primary site</b>			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Malignant melanoma in situ</b>			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metastases to bone</b>			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metastases to liver</b>			
subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Metastases to lung</b>			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metastases to pancreas</b>			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to peritoneum			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic gastric cancer			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Metastatic malignant melanoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic renal cell carcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Mucinous breast carcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoclonal gammopathy			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mixed hepatocellular cholangiocarcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myelodysplastic syndrome			

subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Myelodysplastic syndrome with single lineage dysplasia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myeloproliferative neoplasm			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasopharyngeal cancer			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm prostate			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer stage IV			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell lung cancer stage II			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour of the lung metastatic			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine tumour of the lung			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma metastatic			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatic carcinoma metastatic			
subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pancreatic neoplasm			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pancreatic neuroendocrine tumour			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parathyroid tumour benign			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary renal cell carcinoma			

subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Plasma cell myeloma			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polycythaemia vera			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	6 / 1766 (0.34%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer metastatic			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Prostate cancer recurrent			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer stage II			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			

subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer metastatic			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal adenocarcinoma			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal cancer			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal neoplasm			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectosigmoid cancer			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Recurrent cancer			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cancer			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma stage I			



subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal neoplasm			
subjects affected / exposed	1 / 1766 (0.06%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 1	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal oncocytoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Serous cystadenocarcinoma ovary			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small cell lung cancer metastatic			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Small intestine neuroendocrine tumour			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue sarcoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Small cell lung cancer			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of the hypopharynx			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell cancer of the renal pelvis and ureter			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			
subjects affected / exposed	5 / 1766 (0.28%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 6	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine leiomyoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval cancer stage 0			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			

Accelerated hypertension			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angiopathy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm			
subjects affected / exposed	4 / 1766 (0.23%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic aneurysm rupture			
subjects affected / exposed	0 / 1766 (0.00%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 4	
Aortic dilatation			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic dissection			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Aortic stenosis			
subjects affected / exposed	2 / 1766 (0.11%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	0 / 2	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Aortic thrombosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arterial disorder			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriosclerosis			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	1 / 3	0 / 2	
deaths causally related to treatment / all	1 / 1	0 / 1	
Behcet's syndrome			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure fluctuation			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood pressure inadequately controlled			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Claudication of jaw muscles			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	5 / 1766 (0.28%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	0 / 7	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diabetic macroangiopathy			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic vascular disorder			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry gangrene			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism arterial			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Extremity necrosis			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Granulomatosis with polyangiitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemodynamic instability			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			

subjects affected / exposed	17 / 1766 (0.96%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	0 / 19	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	7 / 1766 (0.40%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	0 / 7	1 / 10	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypertensive emergency			
subjects affected / exposed	4 / 1766 (0.23%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hypertensive urgency			
subjects affected / exposed	6 / 1766 (0.34%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	0 / 6	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	7 / 1766 (0.40%)	14 / 1767 (0.79%)	
occurrences causally related to treatment / all	0 / 7	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypovolaemic shock			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Iliac artery occlusion			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iliac artery stenosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermittent claudication			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leriche syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Lymphoedema			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurogenic shock			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	3 / 1766 (0.17%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	19 / 1766 (1.08%)	10 / 1767 (0.57%)	
occurrences causally related to treatment / all	0 / 29	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery aneurysm			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery occlusion			

subjects affected / exposed	4 / 1766 (0.23%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery stenosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	9 / 1766 (0.51%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 9	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peripheral vascular disorder			
subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral vascular haematoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock haemorrhagic			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Superficial vein thrombosis			



subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systolic hypertension			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular occlusion			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vascular shunt			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vasculitis necrotising			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Abdominal hernia repair			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula operation			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker removal			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac pacemaker replacement			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract operation			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystectomy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery bypass			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemodialysis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip arthroplasty			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip surgery			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia repair			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee arthroplasty			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leg amputation			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Knee operation			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Percutaneous coronary intervention			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal transplant			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin lesion removal			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal decompression			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fusion surgery			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toe amputation			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transcatheter aortic valve implantation			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	7 / 1766 (0.40%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac death			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Chest discomfort			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Chest pain			

subjects affected / exposed	5 / 1766 (0.28%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complication associated with device			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	30 / 1766 (1.70%)	21 / 1767 (1.19%)	
occurrences causally related to treatment / all	0 / 30	0 / 21	
deaths causally related to treatment / all	0 / 30	0 / 21	
Device related thrombosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gait disturbance			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
General symptom			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			

subjects affected / exposed	4 / 1766 (0.23%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperplasia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperpyrexia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypothermia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired healing			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inflammation			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Localised oedema			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malaise			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal hypertrophy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	9 / 1766 (0.51%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 9	0 / 5	
Non-cardiac chest pain			
subjects affected / exposed	8 / 1766 (0.45%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 8	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	4 / 1766 (0.23%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	1 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peripheral swelling			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			

subjects affected / exposed	7 / 1766 (0.40%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 2	
Stent-graft endoleak			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	3 / 1766 (0.17%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 3	0 / 4	
Sudden death			
subjects affected / exposed	10 / 1766 (0.57%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 10	0 / 5	
deaths causally related to treatment / all	0 / 10	0 / 5	
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ulcer haemorrhage			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent occlusion			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Amyloidosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaphylactic reaction			



subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contrast media allergy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypersensitivity			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Primary amyloidosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Reproductive system and breast disorders			
Adnexa uteri mass			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abnormal uterine bleeding			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Balanoposthitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign prostatic hyperplasia			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colpocele			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intermenstrual bleeding			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian cyst			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatitis			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular pain			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine polyp			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine prolapse			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterovaginal prolapse			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	32 / 1766 (1.81%)	30 / 1767 (1.70%)	
occurrences causally related to treatment / all	0 / 37	0 / 31	
deaths causally related to treatment / all	0 / 14	0 / 12	
Acute pulmonary oedema			
subjects affected / exposed	12 / 1766 (0.68%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 13	0 / 3	
deaths causally related to treatment / all	0 / 4	0 / 1	
Aspiration			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Choking			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Chronic obstructive pulmonary disease			
subjects affected / exposed	9 / 1766 (0.51%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	0 / 10	0 / 7	
deaths causally related to treatment / all	0 / 1	0 / 2	
Chronic respiratory disease			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cough			

subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	11 / 1766 (0.62%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	0 / 12	0 / 12	
deaths causally related to treatment / all	0 / 2	0 / 2	
Dyspnoea exertional			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrothorax			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercapnia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			

subjects affected / exposed	4 / 1766 (0.23%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Interstitial lung disease			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nasal polyps			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthopnoea			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oropharyngeal pain			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive sleep apnoea syndrome			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	5 / 1766 (0.28%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	0 / 6	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumothorax			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Pneumonitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary congestion			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	11 / 1766 (0.62%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	0 / 12	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pulmonary fibrosis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary infarction			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	14 / 1766 (0.79%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	0 / 14	0 / 10	
deaths causally related to treatment / all	0 / 5	0 / 2	
Pulmonary pain			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory acidosis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory arrest			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory distress			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	11 / 1766 (0.62%)	20 / 1767 (1.13%)	
occurrences causally related to treatment / all	0 / 12	0 / 20	
deaths causally related to treatment / all	0 / 4	0 / 9	
Vasomotor rhinitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Abnormal behaviour			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adjustment disorder			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bipolar disorder			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	1 / 1766 (0.06%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	3 / 1766 (0.17%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hallucination			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Insomnia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panic attack			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranoia			



subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-traumatic stress disorder			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicide attempt			
subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device malfunction			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device occlusion			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prosthetic cardiac valve malfunction			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			
subjects affected / exposed	4 / 1766 (0.23%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			

subjects affected / exposed	1 / 1766 (0.06%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	1 / 1	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	15 / 1766 (0.85%)	12 / 1767 (0.68%)	
occurrences causally related to treatment / all	4 / 16	6 / 12	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cholecystitis chronic			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholelithiasis			
subjects affected / exposed	12 / 1766 (0.68%)	13 / 1767 (0.74%)	
occurrences causally related to treatment / all	6 / 12	5 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestatic liver injury			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic hepatic failure			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			

subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder enlargement			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemobilia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hepatic cyst			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic mass			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hepatitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis cholestatic			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatorenal syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Hydrocholecystitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver injury			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver disorder			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post cholecystectomy syndrome			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose fluctuation			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood folate decreased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood glucose abnormal			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain natriuretic peptide increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood potassium increased			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerular filtration rate decreased			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glomerular filtration rate abnormal			

subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic enzyme increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Laboratory test abnormal			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulse abnormal			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
SARS-CoV-2 test positive			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tidal volume decreased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin T increased			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			

subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count increased			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia postoperative			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	5 / 1766 (0.28%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arteriovenous fistula occlusion			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain contusion			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central cord syndrome			

subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical vertebral fracture			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contrast media toxicity			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Contusion			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery restenosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary vascular graft occlusion			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary vascular graft stenosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			



subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Craniocerebral injury			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Craniofacial fracture			
subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endotracheal intubation complication			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	20 / 1766 (1.13%)	17 / 1767 (0.96%)	
occurrences causally related to treatment / all	0 / 21	0 / 18	
deaths causally related to treatment / all	0 / 1	0 / 1	
Femoral neck fracture			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femur fracture			
subjects affected / exposed	4 / 1766 (0.23%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 4	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibula fracture			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flatback syndrome			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exposure to toxic agent			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Haemodialysis complication			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Head injury			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	3 / 1766 (0.17%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	4 / 1766 (0.23%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 4	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	1 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intentional overdose			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Joint dislocation			

subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint injury			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ligament sprain			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fracture			
subjects affected / exposed	4 / 1766 (0.23%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 4	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple injuries			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle strain			

subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	0 / 1766 (0.00%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Patella fracture			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Poisoning			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative ileus			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural intestinal perforation			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural pneumothorax			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural shock			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural vomiting			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative renal failure			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radius fracture			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rib fracture			
subjects affected / exposed	4 / 1766 (0.23%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	2 / 1766 (0.11%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 1	
Shoulder fracture			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt malfunction			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shunt occlusion			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin laceration			
subjects affected / exposed	5 / 1766 (0.28%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skull fracture			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue injury			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal column injury			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord injury			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fracture			

subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon injury			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous haematoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	5 / 1766 (0.28%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thermal burn			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thoracic vertebral fracture			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Traumatic intracranial haemorrhage			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Traumatic ulcer			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular graft stenosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound evisceration			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound necrosis			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Atrial septal defect			



subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dilatation intrahepatic duct congenital			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocele			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertrophic cardiomyopathy			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Phimosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudohypoaldosteronism			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	67 / 1766 (3.79%)	49 / 1767 (2.77%)	
occurrences causally related to treatment / all	3 / 81	1 / 52	
deaths causally related to treatment / all	1 / 13	0 / 10	
Acute left ventricular failure			
subjects affected / exposed	6 / 1766 (0.34%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Acute coronary syndrome			

subjects affected / exposed	4 / 1766 (0.23%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 2	
Angina pectoris			
subjects affected / exposed	16 / 1766 (0.91%)	13 / 1767 (0.74%)	
occurrences causally related to treatment / all	0 / 16	0 / 16	
deaths causally related to treatment / all	0 / 0	0 / 1	
Angina unstable			
subjects affected / exposed	22 / 1766 (1.25%)	12 / 1767 (0.68%)	
occurrences causally related to treatment / all	0 / 24	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve disease mixed			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve incompetence			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic valve stenosis			
subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			
subjects affected / exposed	3 / 1766 (0.17%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 2	
Arteriosclerosis coronary artery			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block second degree			

subjects affected / exposed	2 / 1766 (0.11%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrial fibrillation			
subjects affected / exposed	22 / 1766 (1.25%)	31 / 1767 (1.75%)	
occurrences causally related to treatment / all	1 / 31	0 / 35	
deaths causally related to treatment / all	0 / 2	0 / 2	
Atrial flutter			
subjects affected / exposed	7 / 1766 (0.40%)	11 / 1767 (0.62%)	
occurrences causally related to treatment / all	0 / 10	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial tachycardia			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block complete			
subjects affected / exposed	4 / 1766 (0.23%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 4	1 / 5	
deaths causally related to treatment / all	0 / 1	0 / 0	
Atrioventricular block first degree			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradyarrhythmia			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bradycardia			
subjects affected / exposed	6 / 1766 (0.34%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	0 / 6	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	18 / 1766 (1.02%)	18 / 1767 (1.02%)	
occurrences causally related to treatment / all	0 / 19	0 / 19	
deaths causally related to treatment / all	0 / 2	0 / 4	
Cardiac failure acute			
subjects affected / exposed	22 / 1766 (1.25%)	27 / 1767 (1.53%)	
occurrences causally related to treatment / all	1 / 32	0 / 30	
deaths causally related to treatment / all	0 / 6	0 / 10	
Cardiac hypertrophy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac aneurysm			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	14 / 1766 (0.79%)	16 / 1767 (0.91%)	
occurrences causally related to treatment / all	1 / 14	0 / 18	
deaths causally related to treatment / all	1 / 10	0 / 12	
Cardiac asthma			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cardiac failure			
subjects affected / exposed	66 / 1766 (3.74%)	48 / 1767 (2.72%)	
occurrences causally related to treatment / all	3 / 89	0 / 63	
deaths causally related to treatment / all	0 / 12	0 / 6	
Cardiac failure congestive			
subjects affected / exposed	49 / 1766 (2.77%)	33 / 1767 (1.87%)	
occurrences causally related to treatment / all	2 / 56	0 / 40	
deaths causally related to treatment / all	1 / 7	0 / 3	
Cardiac valve disease			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	5 / 1766 (0.28%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 5	0 / 2	
Cardiogenic shock			
subjects affected / exposed	6 / 1766 (0.34%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 4	0 / 1	
Cardiomegaly			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiomyopathy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			

subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 3	0 / 2	
Cardiorenal syndrome			
subjects affected / exposed	3 / 1766 (0.17%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiovascular disorder			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cardiovascular insufficiency			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac ventricular thrombosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic left ventricular failure			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cor pulmonale			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	28 / 1766 (1.59%)	31 / 1767 (1.75%)	
occurrences causally related to treatment / all	1 / 29	1 / 37	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronary artery occlusion			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			
subjects affected / exposed	10 / 1766 (0.57%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	1 / 11	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery thrombosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Hypertensive heart disease			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Ischaemic cardiomyopathy			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Left ventricular dysfunction			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Left ventricular failure			
subjects affected / exposed	11 / 1766 (0.62%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 11	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 0	
Mitral valve stenosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mitral valve incompetence			

subjects affected / exposed	2 / 1766 (0.11%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 1	
Myocardial fibrosis			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Myocardial infarction			
subjects affected / exposed	15 / 1766 (0.85%)	15 / 1767 (0.85%)	
occurrences causally related to treatment / all	0 / 15	0 / 15	
deaths causally related to treatment / all	0 / 7	0 / 6	
Myocardial ischaemia			
subjects affected / exposed	3 / 1766 (0.17%)	10 / 1767 (0.57%)	
occurrences causally related to treatment / all	0 / 3	1 / 10	
deaths causally related to treatment / all	0 / 1	1 / 1	
Myocarditis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodal rhythm			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nodal arrhythmia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pacing induced cardiomyopathy			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Palpitations			



subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis uraemic			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial calcification			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	4 / 1766 (0.23%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary valve incompetence			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary valve stenosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Right ventricular failure			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sinus bradycardia			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus node dysfunction			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systolic dysfunction			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachyarrhythmia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tricuspid valve incompetence			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachycardia			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular tachyarrhythmia			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular arrhythmia			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Nervous system disorders			
Altered state of consciousness			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ataxia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal ganglia infarction			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bell's palsy			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autonomic nervous system imbalance			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autonomic neuropathy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain compression			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Brain injury			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Brain oedema			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Brain stem infarction			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem stroke			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid arteriosclerosis			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery occlusion			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carotid artery stenosis			
subjects affected / exposed	3 / 1766 (0.17%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar infarction			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebellar stroke			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral artery occlusion			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral atrophy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral cyst			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cerebral haemorrhage			

subjects affected / exposed	4 / 1766 (0.23%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 3	0 / 1	
Cerebral infarction			
subjects affected / exposed	5 / 1766 (0.28%)	11 / 1767 (0.62%)	
occurrences causally related to treatment / all	0 / 5	2 / 12	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cerebral ischaemia			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	13 / 1766 (0.74%)	15 / 1767 (0.85%)	
occurrences causally related to treatment / all	1 / 13	0 / 15	
deaths causally related to treatment / all	0 / 5	0 / 4	
Cerebrovascular disorder			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervicobrachial syndrome			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			

subjects affected / exposed	0 / 1766 (0.00%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cranial nerve paralysis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic neuropathy			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic autonomic neuropathy			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness postural			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolic stroke			
subjects affected / exposed	4 / 1766 (0.23%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalomalacia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalopathy			

subjects affected / exposed	3 / 1766 (0.17%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epilepsy			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hemiparesis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hepatic encephalopathy			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Haemorrhagic stroke			



subjects affected / exposed	5 / 1766 (0.28%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 4	0 / 2	
Haemorrhagic transformation stroke			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	3 / 1766 (0.17%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic coma			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic encephalopathy			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic seizure			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemic unconsciousness			

subjects affected / exposed	4 / 1766 (0.23%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	2 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
IIIrd nerve paralysis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intracranial aneurysm			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intraventricular haemorrhage			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cerebral infarction			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	1 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Ischaemic stroke			
subjects affected / exposed	34 / 1766 (1.93%)	23 / 1767 (1.30%)	
occurrences causally related to treatment / all	1 / 36	0 / 23	
deaths causally related to treatment / all	0 / 6	0 / 1	
Lacunar infarction			
subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar stroke			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Loss of consciousness			

subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar radiculopathy			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Monoplegia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Middle cerebral artery stroke			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic encephalopathy			
subjects affected / exposed	3 / 1766 (0.17%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 1	0 / 1	
Myelopathy			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple sclerosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Neuropathy peripheral			

subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parkinson's disease			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post herpetic neuralgia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Radiculopathy			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ruptured cerebral aneurysm			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Sciatica			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			

subjects affected / exposed	3 / 1766 (0.17%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure like phenomena			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal epidural haematoma			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status epilepticus			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subarachnoid haemorrhage			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	9 / 1766 (0.51%)	14 / 1767 (0.79%)	
occurrences causally related to treatment / all	0 / 9	3 / 16	
deaths causally related to treatment / all	0 / 1	0 / 0	
Thalamus haemorrhage			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic encephalopathy			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tension headache			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tethered cord syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thalamic infarction			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thalamic stroke			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	13 / 1766 (0.74%)	15 / 1767 (0.85%)	
occurrences causally related to treatment / all	1 / 14	0 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper motor neurone lesion			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular dementia			

subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uraemic encephalopathy			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebrobasilar stroke			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo CNS origin			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular encephalopathy			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	24 / 1766 (1.36%)	18 / 1767 (1.02%)	
occurrences causally related to treatment / all	2 / 28	0 / 22	
deaths causally related to treatment / all	0 / 1	0 / 0	
Blood loss anaemia			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coagulopathy			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated intravascular coagulation			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypochromic anaemia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	5 / 1766 (0.28%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocytosis			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microcytic anaemia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normocytic anaemia			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrogenic anaemia			



subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	5 / 1766 (0.28%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Splenic infarction			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presbycusis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo			
subjects affected / exposed	0 / 1766 (0.00%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	0 / 0	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertigo positional			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Blepharitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blindness unilateral			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	13 / 1766 (0.74%)	22 / 1767 (1.25%)	
occurrences causally related to treatment / all	0 / 16	0 / 27	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinal oedema			
subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic retinopathy			
subjects affected / exposed	9 / 1766 (0.51%)	12 / 1767 (0.68%)	
occurrences causally related to treatment / all	1 / 9	6 / 15	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epiretinal membrane			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Exfoliation glaucoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eyelid ptosis			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glaucoma			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Maculopathy			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular oedema			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular hole			
subjects affected / exposed	0 / 1766 (0.00%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ocular ischaemic syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal artery occlusion			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein occlusion			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein thrombosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinopathy proliferative			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tractional retinal detachment			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulcerative keratitis			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vision blurred			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			

subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain lower			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	6 / 1766 (0.34%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	2 / 6	1 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal incarcerated hernia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia obstructive			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	1 / 1766 (0.06%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 1	2 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal distension			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure haemorrhage			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal ulcer haemorrhage			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortoenteric fistula			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Change of bowel habit			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	4 / 1766 (0.23%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	2 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	1 / 2	0 / 4	
deaths causally related to treatment / all	1 / 1	0 / 0	
Constipation			
subjects affected / exposed	5 / 1766 (0.28%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	1 / 6	2 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diarrhoea			

subjects affected / exposed	4 / 1766 (0.23%)	10 / 1767 (0.57%)	
occurrences causally related to treatment / all	0 / 4	1 / 11	
deaths causally related to treatment / all	0 / 0	0 / 1	
Diverticulum			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer perforation			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Dysphagia			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erosive oesophagitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer perforation			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric polyps			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer haemorrhage			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Food poisoning			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	3 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	10 / 1766 (0.57%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	1 / 10	0 / 9	
deaths causally related to treatment / all	0 / 2	0 / 0	
Gastrointestinal polyp haemorrhage			



subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	2 / 2	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gingival bleeding			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis haemorrhagic			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematemesis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoids			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hernial eventration			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hiatus hernia			

subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoaesthesia oral			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus paralytic			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Impaired gastric emptying			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated inguinal hernia			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incarcerated umbilical hernia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	3 / 1766 (0.17%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	1 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal haematoma			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal ischaemia			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Intestinal mass			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
Intestinal perforation			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal polyp			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritable bowel syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal obstruction			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine perforation			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Large intestine polyp			
subjects affected / exposed	8 / 1766 (0.45%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	1 / 10	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower gastrointestinal haemorrhage			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mechanical ileus			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mallory-Weiss syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 1766 (0.06%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	1 / 1	3 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising oesophagitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal varices haemorrhage			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal stenosis			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal food impaction			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal fistula			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Obstructive pancreatitis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic failure			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic pseudocyst			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatitis acute			
subjects affected / exposed	5 / 1766 (0.28%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	2 / 5	3 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pancreatitis chronic			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis necrotising			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Peritoneocutaneous fistula			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proctitis			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal ulcer			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haematoma			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	1 / 2	0 / 6	
deaths causally related to treatment / all	0 / 1	0 / 0	
Small intestine polyp			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Strangulated umbilical hernia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	2 / 1766 (0.11%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 2	
Ulcerative gastritis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Umbilical hernia, obstructive			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uraemic gastropathy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vomiting			

subjects affected / exposed	5 / 1766 (0.28%)	11 / 1767 (0.62%)	
occurrences causally related to treatment / all	0 / 5	5 / 11	
deaths causally related to treatment / all	0 / 0	0 / 1	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blister			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decubitus ulcer			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal cyst			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	12 / 1766 (0.68%)	11 / 1767 (0.62%)	
occurrences causally related to treatment / all	0 / 12	0 / 14	
deaths causally related to treatment / all	0 / 0	0 / 1	
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eczema			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Linear IgA disease			



subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pemphigoid			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Purpura			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin necrosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin ulcer			
subjects affected / exposed	7 / 1766 (0.40%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 13	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stasis dermatitis			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stevens-Johnson syndrome			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	123 / 1766 (6.96%)	124 / 1767 (7.02%)	
occurrences causally related to treatment / all	3 / 143	5 / 165	
deaths causally related to treatment / all	0 / 15	0 / 15	
Albuminuria			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anuria			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Azotaemia			
subjects affected / exposed	3 / 1766 (0.17%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 1	
Calculus urinary			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Chronic kidney disease			
subjects affected / exposed	37 / 1766 (2.10%)	42 / 1767 (2.38%)	
occurrences causally related to treatment / all	0 / 37	6 / 48	
deaths causally related to treatment / all	0 / 1	0 / 1	
Cystitis haemorrhagic			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic end stage renal disease			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic nephropathy			
subjects affected / exposed	5 / 1766 (0.28%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	0 / 6	1 / 12	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic complication renal			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
End stage renal disease			
subjects affected / exposed	36 / 1766 (2.04%)	31 / 1767 (1.75%)	
occurrences causally related to treatment / all	3 / 37	2 / 33	
deaths causally related to treatment / all	0 / 5	0 / 2	
Glomerulonephritis proliferative			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	4 / 1766 (0.23%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobinuria			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	4 / 1766 (0.23%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypertensive nephropathy			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interacapillary glomerulosclerosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukocyturia			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrotic syndrome			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy toxic			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	5 / 1766 (0.28%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	1 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oliguria			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Proteinuria			
subjects affected / exposed	4 / 1766 (0.23%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst			

subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst ruptured			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal disorder			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal artery stenosis			
subjects affected / exposed	4 / 1766 (0.23%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	17 / 1766 (0.96%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	0 / 17	0 / 8	
deaths causally related to treatment / all	0 / 3	0 / 3	
Renal injury			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal mass			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular acidosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular necrosis			

subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	18 / 1766 (1.02%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	1 / 21	1 / 9	
deaths causally related to treatment / all	0 / 4	0 / 0	
Subcapsular renal haematoma			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	0 / 1766 (0.00%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral stenosis			
subjects affected / exposed	0 / 1766 (0.00%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	0 / 1766 (0.00%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	0 / 0	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Goitre			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism primary			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Ankylosing spondylitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Antisynthetase syndrome			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis reactive			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthralgia			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back disorder			

subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	3 / 1766 (0.17%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	1 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	4 / 1766 (0.23%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cervical spinal stenosis			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Costochondritis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot deformity			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty arthritis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gouty tophus			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			



subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorder			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc displacement			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	2 / 1766 (0.11%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 2	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuropathic arthropathy			

subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	9 / 1766 (0.51%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	0 / 9	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 1	
Osteoporosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periarthritis			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polymyalgia rheumatica			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriatic arthropathy			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal osteoarthritis			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondyloarthropathy			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal stenosis			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon pain			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vertebral foraminal stenosis			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal wall abscess			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute sinusitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess limb			
subjects affected / exposed	2 / 1766 (0.11%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal abscess			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis			
subjects affected / exposed	5 / 1766 (0.28%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	0 / 5	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Appendicitis perforated			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis bacterial			
subjects affected / exposed	5 / 1766 (0.28%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 5	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			

subjects affected / exposed	5 / 1766 (0.28%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bacterial infection			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial prostatitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Beta haemolytic streptococcal infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Biliary tract infection			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	74 / 1766 (4.19%)	58 / 1767 (3.28%)	
occurrences causally related to treatment / all	0 / 74	1 / 59	
deaths causally related to treatment / all	0 / 21	0 / 23	
Bone abscess			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	7 / 1766 (0.40%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 7	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis infective			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	83 / 1766 (4.70%)	68 / 1767 (3.85%)	
occurrences causally related to treatment / all	0 / 83	0 / 68	
deaths causally related to treatment / all	0 / 22	0 / 24	
Candida infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Candida sepsis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carbuncle			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	22 / 1766 (1.25%)	12 / 1767 (0.68%)	
occurrences causally related to treatment / all	0 / 31	0 / 17	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cellulitis staphylococcal			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chagas' cardiomyopathy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis infective			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chorioretinitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complicated appendicitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium colitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Clostridium difficile colitis			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronavirus infection			

subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Coronavirus pneumonia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	4 / 1766 (0.23%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dengue fever			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic gangrene			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related sepsis			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			
subjects affected / exposed	7 / 1766 (0.40%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	0 / 8	0 / 8	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diverticulitis			



subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis intestinal haemorrhagic			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Emphysematous cystitis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis bacterial			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Endophthalmitis			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis bacterial			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis viral			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			

subjects affected / exposed	3 / 1766 (0.17%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	0 / 3	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Escherichia infection			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Fournier's gangrene			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungal oesophagitis			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungal peritonitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder empyema			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	11 / 1766 (0.62%)	10 / 1767 (0.57%)	
occurrences causally related to treatment / all	0 / 12	0 / 14	
deaths causally related to treatment / all	0 / 1	0 / 2	
Gastroenteritis			
subjects affected / exposed	6 / 1766 (0.34%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	0 / 6	1 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis bacterial			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis clostridial			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemophilus infection			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma infection			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis B			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes virus infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster infection neurological			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected fistula			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected skin ulcer			

subjects affected / exposed	4 / 1766 (0.23%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Infection			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Infectious pleural effusion			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective aortitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral discitis			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratitis bacterial			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella urinary tract infection			

subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine infection			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Localised infection			
subjects affected / exposed	2 / 1766 (0.11%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	1 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Meningoencephalitis herpetic			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Necrotising fasciitis			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Osteomyelitis			
subjects affected / exposed	13 / 1766 (0.74%)	9 / 1767 (0.51%)	
occurrences causally related to treatment / all	0 / 15	0 / 11	
deaths causally related to treatment / all	0 / 1	0 / 0	
Osteomyelitis acute			

subjects affected / exposed	1 / 1766 (0.06%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orchitis			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nosocomial infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis bacterial			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis media			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parapharyngeal space infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Penile abscess			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perinephric abscess			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	75 / 1766 (4.25%)	66 / 1767 (3.74%)	
occurrences causally related to treatment / all	0 / 87	0 / 70	
deaths causally related to treatment / all	0 / 14	0 / 8	
Peritonitis			
subjects affected / exposed	7 / 1766 (0.40%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pleurisy viral			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Periorbital cellulitis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia staphylococcal			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			



subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post-acute COVID-19 syndrome			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	4 / 1766 (0.23%)	6 / 1767 (0.34%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 2	0 / 3	
Pneumonia bacterial			
subjects affected / exposed	11 / 1766 (0.62%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 11	0 / 4	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pneumonia influenzal			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia klebsiella			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia legionella			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia pseudomonal			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			

subjects affected / exposed	3 / 1766 (0.17%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudoaneurysm infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoas abscess			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	4 / 1766 (0.23%)	5 / 1767 (0.28%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	4 / 1766 (0.23%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pyelonephritis chronic			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal abscess			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	3 / 1766 (0.17%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
SARS-CoV-2 sepsis			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Scrotal abscess			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	23 / 1766 (1.30%)	17 / 1767 (0.96%)	
occurrences causally related to treatment / all	0 / 24	0 / 20	
deaths causally related to treatment / all	0 / 9	0 / 5	
Septic encephalopathy			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic pulmonary embolism			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Serratia infection			

subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Severe acute respiratory syndrome			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Shunt infection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	14 / 1766 (0.79%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	0 / 14	0 / 8	
deaths causally related to treatment / all	0 / 9	0 / 7	
Soft tissue infection			
subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Streptococcal sepsis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spontaneous bacterial peritonitis			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	3 / 1766 (0.17%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 1	
Staphylococcal infection			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	3 / 1766 (0.17%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Subcutaneous abscess			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superinfection			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Suspected COVID-19			
subjects affected / exposed	3 / 1766 (0.17%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 3	0 / 0	
Urinary tract candidiasis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	27 / 1766 (1.53%)	23 / 1767 (1.30%)	
occurrences causally related to treatment / all	0 / 30	1 / 27	
deaths causally related to treatment / all	0 / 1	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	2 / 1766 (0.11%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection pseudomonal			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	3 / 1766 (0.17%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Upper respiratory tract infection			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular device infection			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vulval abscess			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			

subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Abnormal loss of weight			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	2 / 1766 (0.11%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 2	2 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dehydration			
subjects affected / exposed	10 / 1766 (0.57%)	10 / 1767 (0.57%)	
occurrences causally related to treatment / all	0 / 10	1 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	7 / 1766 (0.40%)	10 / 1767 (0.57%)	
occurrences causally related to treatment / all	0 / 9	0 / 12	
deaths causally related to treatment / all	0 / 0	0 / 2	
Diabetic metabolic decompensation			
subjects affected / exposed	6 / 1766 (0.34%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 6	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	5 / 1766 (0.28%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diabetes mellitus inadequate control			

subjects affected / exposed	7 / 1766 (0.40%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	1 / 7	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Electrolyte imbalance			
subjects affected / exposed	1 / 1766 (0.06%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fluid retention			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	4 / 1766 (0.23%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperammonaemia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	11 / 1766 (0.62%)	8 / 1767 (0.45%)	
occurrences causally related to treatment / all	0 / 15	1 / 11	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	4 / 1766 (0.23%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			



subjects affected / exposed	23 / 1766 (1.30%)	15 / 1767 (0.85%)	
occurrences causally related to treatment / all	0 / 24	1 / 18	
deaths causally related to treatment / all	0 / 1	0 / 1	
Hypertriglyceridaemia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperuricaemia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypervolaemia			
subjects affected / exposed	15 / 1766 (0.85%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 19	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophosphataemia			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovitaminosis			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	0 / 1766 (0.00%)	2 / 1767 (0.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoalbuminaemia			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypocalcaemia			

subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoglycaemia			
subjects affected / exposed	24 / 1766 (1.36%)	22 / 1767 (1.25%)	
occurrences causally related to treatment / all	14 / 27	7 / 23	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	4 / 1766 (0.23%)	4 / 1767 (0.23%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	5 / 1766 (0.28%)	7 / 1767 (0.40%)	
occurrences causally related to treatment / all	0 / 5	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	1 / 1766 (0.06%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			
subjects affected / exposed	2 / 1766 (0.11%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	0 / 1766 (0.00%)	1 / 1767 (0.06%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			

subjects affected / exposed	7 / 1766 (0.40%)	3 / 1767 (0.17%)	
occurrences causally related to treatment / all	0 / 7	0 / 3	
deaths causally related to treatment / all	0 / 1	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitamin D deficiency			
subjects affected / exposed	1 / 1766 (0.06%)	0 / 1767 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	Semaglutide	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	522 / 1766 (29.56%)	507 / 1767 (28.69%)	
Eye disorders			
Diabetic retinopathy			
subjects affected / exposed	325 / 1766 (18.40%)	339 / 1767 (19.19%)	
occurrences (all)	381	394	
Infections and infestations			
COVID-19			
subjects affected / exposed	246 / 1766 (13.93%)	221 / 1767 (12.51%)	
occurrences (all)	260	238	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
03 November 2020	1) Addition of COVID-19 related mitigations, including co-participation. 2) Increased sample size, and addressed changes to the statistical testing.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The planned interim analysis was carried out according to the procedures described in the protocol. The prespecified criteria for early termination based on efficacy were met and the trial was consequently terminated early.

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/36651820>